Biotech platform developing programmable nanocarrier delivery systems and engineered mRNA therapeutics targeting cancer, lung, and neurodegenerative diseases.
Nuntius Therapeutics is a biotech company building cell-specific genetic medicine technology through three capability pillars: programmable non-immunogenic nanocarriers that can target tissues beyond the liver; ML models that predict carrier quality and performance across millions of candidates; and engineered mRNA with superior protein expression compared to clinically used mRNA. The company is advancing a drug pipeline targeting cancer, lung diseases, and neurodegenerative diseases, with operations in Delaware, USA and London, UK. Nuntius Therapeutics is a product of Nuntius Therapeutics.